Created at Source Raw Value Validated value
Nov. 6, 2020, 11:45 p.m. oms

1) Seroconversion for SARS-CoV-2 IgM; IgA and IgG by treatment arm and patient outcome;2) Quantitative levels of antibodies (IgM; IgG; IgA) specific for SARS-CoV-2;3) Frequency of SARS-CoV-2-specific effector/memory CD4+ and CD8+ T cells ;4) Proportions of (poly)functional SARS-CoV-2-specific T cells

1) Seroconversion for SARS-CoV-2 IgM; IgA and IgG by treatment arm and patient outcome;2) Quantitative levels of antibodies (IgM; IgG; IgA) specific for SARS-CoV-2;3) Frequency of SARS-CoV-2-specific effector/memory CD4+ and CD8+ T cells ;4) Proportions of (poly)functional SARS-CoV-2-specific T cells